Reckitt Benckiser
1 products tracked · names used in filings: Reckitt Benckiser
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 22 Dec 2025🇺🇸 FDA approval
FDA approves Mucinex 12Hr Cold & Fever Multi-Symptom (dextromethorphan hydrobromide, guaifenesin, naproxen sodium): new combination
Reckitt Benckiser; NDA217338; New combination; tablet, extended release · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Mucinex 12Hr Cold & Fever Multi-Symptom dextromethorphan hydrobromide, guaifenesin, naproxen sodium | Approved | 2025-12-22 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.